Patents by Inventor A. Seetharama Acharya
A. Seetharama Acharya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11065277Abstract: A method of reducing a cerebral tissue pathology associated with a sickle cell disease therapy in a subject is provided using (i) a synthetic high-oxygen affinity hemoglobin-containing molecule or (ii) synthetically treated high-oxygen affinity blood.Type: GrantFiled: November 8, 2016Date of Patent: July 20, 2021Assignee: Albert Einstein College of MedicineInventors: Craig Branch, Seetharama Acharya
-
Publication number: 20180369281Abstract: A method of reducing a cerebral tissue pathology associated with a sickle cell disease therapy in a subject is provided using (i) a synthetic high-oxygen affinity hemoglobin-containing molecule or (ii) synthetically treated high-oxygen affinity blood.Type: ApplicationFiled: November 8, 2016Publication date: December 27, 2018Applicant: ALBERT EINSTEIN COLLGE OF MEDICINE, INC.Inventors: Craig Branch, Seetharama Acharya
-
Publication number: 20170333566Abstract: Described herein are semisynthetic biopolymers comprising: a plurality of polyalkylene glycol chains, a protein, and an antioxidant; wherein the polyalkylene glycol chains are conjugated to the protein through a substituted succinimide linker. In some embodiments, the compounds described herein are conjugated proteins referred to as “semisynthetic supra perfusion agents”, “semisynthetic hybrid biopolymers”, “semisynthetic supra plasma expanders”, or the like. In some embodiments, these compounds mimic the same physiological consequences of high viscosity supra plasma expanders without being highly viscous—i.e. having a viscosity greater than blood.Type: ApplicationFiled: November 16, 2015Publication date: November 23, 2017Inventors: Seetharama A. Acharya, Vivek N. Acharya, Craig Andrew Branch, Sangeetha Thangaswamy
-
Publication number: 20170056381Abstract: The present invention relates to treatments and therapies for anemia conditions and diseases of the blood, and more particular is a therapy for the acute and chronic treatment of sickle cell diseases and thalassemia by administration of pyridoxamine, or a pharmaceutically acceptable salt thereof, optionally in combination with an additional bioactive agent.Type: ApplicationFiled: February 20, 2015Publication date: March 2, 2017Inventors: Steven Isaacman, Seetharama A. Acharya
-
Patent number: 9498537Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.Type: GrantFiled: August 7, 2014Date of Patent: November 22, 2016Assignees: Albert Einstein College of Medicine, Inc., The Regents of the University of CaliforniaInventors: Seetharama A. Acharya, Marcos Intaglietta
-
Publication number: 20160144048Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.Type: ApplicationFiled: January 14, 2016Publication date: May 26, 2016Inventors: Seetharama A. Acharya, Belur N. Manjula
-
Publication number: 20150017146Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.Type: ApplicationFiled: August 7, 2014Publication date: January 15, 2015Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Seetharama A. Acharya, Marcos Intaglietta
-
Patent number: 8859499Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.Type: GrantFiled: March 12, 2013Date of Patent: October 14, 2014Assignees: Albert Einstein College of Medicine of Yeshiva University, The Regents of the University of CaliforniaInventors: Seetharama A. Acharya, Marcos Intaglietta
-
Publication number: 20140256636Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.Type: ApplicationFiled: May 20, 2014Publication date: September 11, 2014Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Belur N. Manjula
-
Patent number: 8741832Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.Type: GrantFiled: June 9, 2006Date of Patent: June 3, 2014Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Belur N. Manjula
-
Patent number: 8697645Abstract: Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins having at least two specific chemical modifications. PEGylated versions of these hemoglobins are also provided, as are certain tetraPEGylated and diPEGylated hemoglobins. Methods of modifying a hemoglobin are additionally provided, as are methods of making a hemoglobin. Pharmaceutical compositions and blood substitutes using these hemoglobins are further provided, as are methods of treating a subject using these pharmaceutical compositions and blood substitutes.Type: GrantFiled: March 12, 2008Date of Patent: April 15, 2014Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Belur N. Manjula
-
Publication number: 20130261061Abstract: A method of improving the efficacy of a blood transfusion into a subject is provided comprising administering a composition comprising an EAF PEGylated-blood protein into the subject, prior to, during, or subsequent to the blood transfusion.Type: ApplicationFiled: March 12, 2013Publication date: October 3, 2013Applicants: The Regents of the University of California, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Marcos Intaglietta
-
Patent number: 8071546Abstract: The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.Type: GrantFiled: June 9, 2006Date of Patent: December 6, 2011Assignees: La Jolla Bioengineering Institute, Albert Einstein College of Medicine of Yeshiva UniversityInventors: Pedro Cabrales, Amy Tsai, Seetharama A. Acharya, Belur N. Manjula
-
Publication number: 20100222260Abstract: The present invention is directed to uses of PEGylated albumins which include methods of treating reduced functional capillary density, reduced blood volume, septic shock and cardiac arrhythmia in a subject, which comprise administering to the subject a therapeutically effective amount of a PEGylated albumin.Type: ApplicationFiled: June 9, 2006Publication date: September 2, 2010Inventors: Pedro Cabrales, Amy Tsai, Seetharama A. Acharya, Belur N. Manjula
-
Publication number: 20100216695Abstract: Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins having at least two specific chemical modifications. PEGylated versions of these hemoglobins are also provided, as are certain tetraPEGylated and diPEGylated hemoglobins. Methods of modifying a hemoglobin are additionally provided, as are methods of making a hemoglobin. Pharmaceutical compositions and blood substitutes using these hemoglobins are further provided, as are methods of treating a subject using these pharmaceutical compositions and blood substitutes.Type: ApplicationFiled: March 12, 2008Publication date: August 26, 2010Inventors: Seetharama A. Acharya, Belur N. Manjula
-
Publication number: 20090298746Abstract: The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide.Type: ApplicationFiled: June 9, 2006Publication date: December 3, 2009Inventors: Seetharama A. Acharya, Belur N. Manjula
-
Publication number: 20090215670Abstract: The present invention provides pegylated hemoglobins comprising a maleimide polyethylene glycol (PEG) conjugated to a thiol moiety of a cysteine residue of hemoglobin, methods of preparing the pegylated hemoglobins, compositions and blood substitutes comprising the pegylated hemoglobins, and methods of treating a subject which comprise administering to the subject blood substitutes comprising vasoinactive pegylated hemoglobins.Type: ApplicationFiled: May 10, 2006Publication date: August 27, 2009Inventors: Seetharama A. Acharya, Belur N. Manjula, Vivek N. Acharya
-
Patent number: 7521174Abstract: The present invention is directed to pegylated red blood cells comprising a polyethylene glycol (PEG) attached to a thiolated amino group on a membrane protein, and to compositions comprising the pegylated red blood cells. The invention also provides methods of preparing pegylated red blood cells comprising reacting red blood cells with a compound that produces a thiolated amino group on a red blood cell membrane protein, and reacting the thiolated red blood cell with a PEG. The invention further provides methods of treatment using pegylated red blood cells.Type: GrantFiled: December 3, 2004Date of Patent: April 21, 2009Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Parimala Nacharaju, Belur N. Manjula
-
Patent number: 7501499Abstract: The present invention provides a hemoglobin molecule (Hb) having six ± one PEG chains, wherein two of said PEG chains are bound to Cys-93 (?) of Hb, and the remaining PEG chains are bound to thiol groups introduced on ?-NH2 of Hb. The present invention also provides a process for preparing a modified hemoglobin molecule (Hb), comprising the steps of: (a) reacting Hb with 8-15 fold excess of iminothiolane to form thiolated Hb; and (b) reacting the thiolated Hb with 16-30 fold excess of PEG functionalized with a maleimide moiety, to form the modified Hb.Type: GrantFiled: December 18, 2003Date of Patent: March 10, 2009Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Belur N. Manjula
-
Patent number: 7169900Abstract: Novel modified hemoglobins comprising polyalkylene glycols and novel methods for making those hemoglobins are provided. One group of modified hemoglobins comprise polyalkylene glycols bonded to the hemoglobin with an amide linkage at Glu-43(?). Additional polyalkylene glycols can also be bonded to the Glu-22(?) and/or the Asp-47(?). These hemoglobins are made by a novel amidation procedure. A second group of modified hemoglobins comprise a polyalkylene glycol covalently bonded to the hemoglobin at the ?-amino of a Val-1(?) or a Val-1(?). Additional polyalkylene glycols can optionally be covalently bonded to a limited number of ?-amino groups. This second group of hemoglobins is made using a novel reductive alkylation procedure. A third group of modified hemoglobins comprise a polyalkylene glycol bonded to a thiol group of the hemoglobin through a phenylsuccinimido linkage, wherein no polyalkylene glycol is bonded to a Cys-93(?).Type: GrantFiled: December 6, 2005Date of Patent: January 30, 2007Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Seetharama A. Acharya, Belur N. Manjula